Navigation Links
Sun Pharma Announces U.S. FTC Clearance for Taro Tender Offer
Date:8/13/2008

MUMBAI, India, Aug. 13 /PRNewswire/ -- Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUN PHARMA, BSE: 524715) today announced that on August 13, 2008, the U.S. Federal Trade Commission (FTC) granted early termination of the antitrust waiting period under the Hart-Scott-Rodino Act (HSR) for the previously announced Tender Offer by Alkaloida Chemical Company Exclusive Group Ltd. (Alkaloida), a subsidiary of Sun Pharma, for all outstanding Ordinary Shares of Taro Pharmaceutical Industries Ltd. (Taro). Clearance under HSR meets one of the conditions to the Tender Offer. The Offer is scheduled to expire at 5:00 p.m., New York City time, on Tuesday, September 2, 2008 unless extended.

The Offer was commenced on June 30, 2008 in order to comply with the terms of the Option Agreement between Alkaloida and the controlling shareholders of Taro. The complete terms and conditions are set out in the Offer to Purchase, which is filed with the U.S. Securities and Exchange Commission. Taro shareholders may obtain copies of all of the offering documents, including the Offer to Purchase, free of charge at the SEC's website (http://www.sec.gov) or by directing a request to MacKenzie Partners, Inc., the Information Agent for the offer, at 105 Madison Avenue, New York, New York 10016, (212) 929-5500 (Call Collect) or Call Toll-Free (800) 322-2885, Email: tenderoffer@mackenziepartners.com.

Greenhill & Co., LLC is acting as the Dealer Manager for the Tender Offer and MacKenzie is acting as the Information Agent for the Tender Offer.

About Sun Pharmaceutical Industries Ltd.

Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, U.S. and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, and orthopedics. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. More information about the company can be found at http://www.sunpharma.com.

Contacts

Uday Baldota Mira Desai

Tel +91 22 6645 5645, Xtn 605 Tel +91 22 6645 5645, Xtn 606

Tel Direct +91 22 66455605 Tel Direct +91 22 66455606

Mobile +91 98670 10529 Mobile +91 98219 23797

E mail uday.baldota@sunpharma.com E mail mira.desai@sunpharma.com

Brunswick Group for Sun Pharma MacKenzie Partners

Nina Devlin / Erin Becker Robert Marese

+1 212 333 3810 +1 212 929 5500

Arad Communications for Sun Pharma Greenhill

Gali Dahan Ashish Contractor

+972 3 7693320 +1 212 389 1537


'/>"/>
SOURCE Sun Pharmaceutical Industries Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. WuXi PharmaTech Announces Second Quarter 2008 Results
2. Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results
3. Lotus Pharmaceuticals Announces Conference Call to Discuss Second Quarter 2008 Results
4. Employee Involvement Is Key to Long-Term Pharmacy Cost Control, Finds Buck Consultants Survey
5. MAP Pharmaceuticals Reports Second Quarter of 2008 Financial Results
6. Triax Pharmaceuticals Launches New Mid-Potency Corticosteroid Vehicle, Locoid Lotion 0.1%
7. KV Pharmaceutical Company Reports Fiscal 2009 First Quarter Results
8. ADVENTRX Pharmaceuticals Reports Second Quarter 2008 Financial Results and Business Update
9. Novis Pharmaceuticals Announces John W. Kilgour as Executive Vice-President of Sales & Marketing
10. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
11. IntelliPharmaCeutics Provides Update on Activities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... 2017 , ... The VA Maryland Health Care System and ... project focused on multiple sclerosis (MS). Led by Christopher M. Jewell, PhD, an ... disease without compromising normal immune function that often occurs during autoimmune diseases. Ultimately ...
(Date:1/18/2017)... Cranbury, NJ (PRWEB) , ... ... ... Times®, the specialty pharmacy industry‚Äôs leading journal and most-read publication among specialty ... Vanderbilt University Medical Center through its Strategic Alliance Partnership (SAP) program, announced ...
(Date:1/18/2017)... ... January 18, 2017 , ... A Palm Beach doctor ... Smile Train, an international charity that provides free surgery to poor children suffering from ... in the past I have run to support the efforts of the American Heart ...
(Date:1/18/2017)... , ... January 18, 2017 , ... The Portee Insurance ... families and business owners in central Maryland and the DC region, is inaugurating a ... kills 787,000 people nationally every year, making it the #1 killer in America. However, ...
(Date:1/18/2017)... ... , ... At Hallmark Nameplate, their commitment to quality is what sets them ... 13485. This certification is another way they are making constant strides to provide all ... need. , The ISO 13485 Certification is a major accomplishment for Hallmark Nameplate and ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... -- Aprima Medical Software, a leading provider of innovative ... revenue cycle management (RCM) solutions for medical practices, ... Healthcare Data Solutions (HDS) of Coral Cables, FL. ... full support for HDS,s customers, which include approximately ... states. Financial terms were not disclosed. ...
(Date:1/18/2017)... JOSE, Calif. , Jan. 18, 2017  Adaptive Sound ... announced today a new partnership with Hyatt Place Nashville/Downtown ... by providing ASTI LectroFan sleep therapy machines in over ... one of the most important parts of having a ... , general manager of Hyatt Place Nashville/Downtown. "We,re pleased ...
(Date:1/18/2017)... PUNE, India , January 18, 2017 According to ... Type and by Application: Global Opportunity Analysis and Industry Forecast, 2014 - 2022," ... expected to reach $1,127 million by 2022, growing at a CAGR of 8.26% ... share, in terms of revenue. Continue Reading ... ...
Breaking Medicine Technology: